Clinical Trials

Clinical Trials

The intensive clinical activity of the IOV is carried out by hospital and university doctors who use cutting-edge treatment programs, with the most accredited conventional cancer treatments. This clinical activity is flanked and complemented by an equally lively research activity that leads to the acquisition of new knowledge for the progress of medicine and offers the possibility to use innovative experimental therapies as therapeutic alternatives, in particular, in patients in whom conventional drugs have failed or have been found to be poorly effective.

This last aspect is achieved thanks to the continuous participation of IOV in clinical trials, both national and international, which involve the use of non-commercialized medicines that are not available on the Italian market. In addition, the Institute’s medical specialists promote, design and carry out clinical trials that explore possible new indications of drugs already on the market, in order to test new therapeutic strategies and thus offer further possibilities of cure.

All clinical trials, whether promoted by the pharmaceutical industry or by non-profit organizations, are conducted at IOV according to strict ethical, regulatory and quality standards. Before being started, each trial must be approved by the Ethics Committee for clinical trials, in accordance with the regulations on clinical trials, the dictates of good clinical practice (GCP) and the ethical principles indicated in the Helsinki Declaration.

For the patients included in the experimental protocols, the main care reference is the research nurses, who represent a flagship of the scientific activity of the IOV, one of only two Italian centers to have this professional figure.

The levels of research, diagnosis and treatment conducted in the Institute place the IOV among the most accredited cancer centers nationwide.

Regimi di salvataggio in pazienti refrattari a Lenalidomide e agli anticorpi monoclonali antiCD38: evidenze dalla real-life (DARE-MM study: DAratumumab and REvlimid REfractory MM)

Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
DARE-MM
Codice EudraCT
NP
Sponsor/Promotore
Fondazione IRCCS Policlinico San Matteo
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Studio di coorte osservazionale prospettico per valutare nei pazienti con linfoma non-Hodgkin a cellule B l’impatto clinico dei nuovi anticorpi monoclonali MAB nella pratica clinica italiana

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
FIL_MAB (Oncologia 1)
Codice EudraCT
NP
Sponsor/Promotore
Fondazione Italiana Linfomi Onlus
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Valutazione mediante test onco-geriatrico G8 del paziente anziano affetto da patologia neoplastica in fase avanzata candidato a ricevere un trattamento innovativo

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
ONC-OLD
Codice EudraCT
NP
Sponsor/Promotore
Università degli Studi di Bologna
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

studio di coorte osservazionale prospettico per valutare nei pazienti con linfoma non-Hodgkin a cellule B l’impatto clinico dei nuovi anticorpi monoclonali MAB nella pratica clinica italiana

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
FIL_MAB
Codice EudraCT
NP
Sponsor/Promotore
Fondazione Italiana Linfomi Onlus
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Valutazione del ruolo della psicoterapia gruppale mediante la pratica del Training Autogeno in pazienti con carcinoma mammario

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
IOV-TA-2023 (ripresentazione)
Codice EudraCT
NP
Sponsor/Promotore
IOV
Tipologia
Sperimentale
Fase
.
Unità Operativa
Principal Investigator

Studio di fase IIIb, a braccio singolo, in aperto, multicentrico su Durvalumab in combinazione con la chemioterapia per il trattamento di prima linea di pazienti con tumori delle vie biliari in stadio avanzato (TOURMALINE)’

Stato
Autorizzato - In attesa di apertura
Codice studio
D4191C00140 (TOURMALINE)_ripresentazione
Codice EudraCT
2022-502043-35-00
Sponsor/Promotore
AstraZeneca AB
Tipologia
Sperimentale
Fase
IIIb
Unità Operativa
Principal Investigator

Search

Status

Last modified: 06/04/2021 15:13

Scroll to Top